Clinical Trial Update: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating HSV-Tk engineered donor lymphocytes for high-risk acute leukemia was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• HSV-Tk engineered donor lymphocytes (HSV-Tk engineered donor lymphocytes)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Acute Leukemia (Category) | Phase 3 | Status: TERMINATED | Results posted: 2021-06-22